Targets › SLC6A2
89 programs from 72 companies in 177 trials: 67 Phase 2, 53 Phase 4, 31 Phase 3, 26 Phase 1; Psychiatry, Other, Oncology; next expected readout Nov 2026.
Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis (By similarity). (UniProt, P23975)
Open in Phaseline: the race on SLC6A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Posttraumatic Stress Disorder | Nov 2026 |
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| All India Institute of Medical Sciences, Bhubaneswar | Dosulepin Tricyclic antidepressant with serotonin and norepinephrine reuptake inhibition | SLC6A4, SLC6A2 | Phase 4 | Somatic Symptom Disorder (DSM-V) | Nov 2026 |
| All India Institute of Medical Sciences, Bhubaneswar | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Somatic Symptom Disorder (DSM-V) | Nov 2026 |
| University of Miami | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | THA | Dec 2026 |
| Rochester Center for Behavioral Medicine | Dyanavel XR Amphetamine derivative; CNS stimulant that increases dopamine and norepinephrine release | SLC6A2, SLC6A3 | Phase 4 | Fatigue | Dec 2026 |
| Daniel Coury | Amphetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent | SLC6A3, SLC6A2 | Phase 4 | ADHD | Jan 2027 |
| Daniel Coury | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | ADHD | Jan 2027 |
| Matthew J O'Brien, PhD, BCBA-D | Amphetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder | Mar 2027 |
| Donald Gilbert, MD, MS, FAAN, FAAP | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder Combined | Mar 2027 |
| VA Office of Research and Development | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Posttraumatic Stress Disorder (PTSD); Epilepsy | Mar 2027 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Reduced noradrenaline by using a lower MAP target (≥55 mmHg) Noradrenaline reuptake inhibition via sympathomimetic vasopressor effect | SLC6A2 | Phase 4 | Cardiogenic Shock | Apr 2027 |
| David Steffens | Desvenlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Major Depressive Disorder | Apr 2027 |
| Wake Forest University Health Sciences | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Depression; Depression in Old Age | May 2027 |
| Montefiore Medical Center | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Back Pain, Low | May 2027 |
| Sunnybrook Health Sciences Centre | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Knee Osteoarthritis | Jul 2027 |
| Dar Clinical Research Inc. | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder | Jul 2027 |
| University of California, Irvine | Phentermine Norepinephrine transporter releasing agent | SLC6A2 | Phase 4 | Obesity | Jul 2027 |
| The Chaim Sheba Medical Center | methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Velocardiofacial Syndrome | Aug 2027 |
| Aarhus University Hospital | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Functional Disorder | Nov 2027 |
| Axsome Therapeutics | Bupropion (AXS-05) Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Major Depressive Disorder; Smoking Cessation; Major Depressive Disorder (MDD); Cigarette Smoking-Related Carcinoma … | Dec 2027 |
| University of California, Irvine | nortriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Ménière | Dec 2027 |
| Supernus Pharmaceuticals | Viloxazine Hydrochloride (SPN-812) Norepinephrine transporter inhibitor | SLC6A2 | Phase 4 | Attention-Deficit/Hyperactivity Disorder | Jan 2028 |
| Northwestern University | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Knee Osteoarthritis | Mar 2028 |
| Johns Hopkins University | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | ADHD - Combined Type | Nov 2028 |
| Benedict Alter | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Knee Osteoarthritis (Knee OA) | Dec 2028 |
| Currax Pharmaceuticals | Bupropion Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Obesity | Jan 2029 |
| The Cleveland Clinic | Phentermine Norepinephrine transporter releasing agent | SLC6A2 | Phase 4 | Liver Cirrhoses | Feb 2029 |
| VA Office of Research and Development | Atomoxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 4 | Posttraumatic Stress Disorder With Attention Defic | Jun 2029 |
| University of Arizona | Atomoxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 4 | Obstructive Sleep Apnea (OSA); Obstructive Sleep Apnea | Jan 2030 |
| Gagan Joshi | Amphetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder (ADHD) | Feb 2030 |
| Children's Hospital Medical Center, Cincinnati | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Feb 2030 |
| Sairam Parthasarathy | Atomoxetine-oxybutynin Norepinephrine reuptake inhibitor combined with muscarinic-3 receptor antagonist to increa | SLC6A2, CHRM3 | Phase 4 | Obstructive Sleep Apnea (OSA) | Mar 2030 |
| Hospital de Clinicas de Porto Alegre | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Disorder With Hyperactivity | Dec 2032 |
| The Royal's Institute of Mental Health Research | Contrave Naltrexone/Bupropion combination; naltrexone is a mu-opioid receptor antagonist and buprop | OPRM1, SLC6A2, SLC6A3 | Phase 4 | Obesity | – |
| NYU Langone Health | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention-deficit/Hyperactivity Disorder | – |
| Florida International University | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | ADHD | – |
| Iuliu Hatieganu University of Medicine and Pharmacy | Nefopam Non-opioid analgesic; mechanism includes monoamine reuptake inhibition and NMDA receptor a | SLC6A2, SLC6A3, GRIN1 | Phase 4 | Pancreatoduodenectomy | – |
| Axsome Therapeutics | Solriamfetol Dose A Dopamine and norepinephrine reuptake inhibitor | SLC6A3, SLC6A2 | Phase 3 | Excessive Sleepiness; Binge-Eating Disorder; ADHD; Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Dec 2026 |
| Parc de Salut Mar | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Chronic Post-surgical Pain | Dec 2026 |
| M.D. Anderson Cancer Center | Methylphenidate Hydrochloride Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Advanced Malignant Neoplasm; Sleep; Prostate Cancer; Prostate Carcinoma … | Dec 2026 |
| University Hospital, Strasbourg, France | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Adult ADHD | May 2027 |
| Tanta University | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Biliary Disease | Jun 2027 |
| Radboud University Medical Center | Atomoxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 3 | Parkinson's Disease (PD) | Jul 2027 |
| Otsuka | Centanafadine (EB-1020) Monoamine transporter inhibitor | SLC6A4, SLC6A3, SLC6A2 | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD) | Aug 2027 |
| Theravance Biopharma | Ampreloxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension | Jan 2028 |
| Axsome Therapeutics | Esreboxetine (AXS-14) Norepinephrine transporter inhibitor | SLC6A2 | Phase 3 | Fibromyalgia | Mar 2028 |
| Dr. Inge Winter | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Bipolar Depression | Jun 2028 |
| Reinier de Graaf Groep | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Breast Cancer | Jan 2029 |
| Odense University Hospital | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Brain Tumor, Pediatric | Dec 2029 |
| Children's Oncology Group | Iobenguane I 131 (I-131) Norepinephrine transporter substrate | SLC6A2 | Phase 3 | Ganglioneuroblastoma | Sep 2030 |
| University College, London | Atomoxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 3 | Alzheimer's Disease (AD) | Mar 2031 |
| Vrije Universiteit Brussel | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Fatigue | – |
| Vrije Universiteit Brussel | Reboxetine Noradrenaline reuptake inhibitor | SLC6A2 | Phase 3 | Fatigue | – |
| Seattle Children's Hospital | Phentermine Norepinephrine transporter releasing agent | SLC6A2 | Phase 2 | Hypothalamic Obesity | Nov 2026 |
| Wright State University | Imipramine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Rosacea; Photosensitivity; Imipramine | Dec 2026 |
| University of Haifa | Reboxetine Noradrenaline reuptake inhibitor | SLC6A2 | Phase 2 | Posttraumatic Stress Disorder; PTSD | Dec 2026 |
| University of Haifa | methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Posttraumatic Stress Disorder; PTSD | Dec 2026 |
| Mayo Clinic | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Interstitial Lung Disease; Refractory Chronic Cough | Dec 2026 |
| Polyclinique de l'Europe | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Inflammatory Bowel Diseases | Dec 2026 |
| M.D. Anderson Cancer Center | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | Dec 2026 |
| Alliance for Clinical Trials in Oncology | Duloxetine Hydrochloride Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Stage II Colorectal Cancer AJCC v8 | Dec 2026 |
| University of Pennsylvania | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Inflammatory Bowel Diseases | Mar 2027 |
| Remedy | Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Post Traumatic Stress Disorder | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | iobenguane I 131 Radioactive iodine-131 targeted to norepinephrine transporters | SLC6A2 | Phase 2 | Neuroblastoma | May 2027 |
| Yan Yang, MD, Ph.D | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Chemotherapy-induced Peripheral Neuropathy | Jul 2027 |
| Definium Therapeutics US | Midomafetamine (DT402) Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Autism Spectrum Disorder | Aug 2027 |
| Sunnybrook Health Sciences Centre | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Alzheimer s Disease | Oct 2027 |
| Medical University of Lodz | Lisdexamfetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor | SLC6A3, SLC6A2, SLC18A2 | Phase 2 | Attention Deficit Disorder with Hyperactivity | Dec 2027 |
| Medical University of Lodz | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Attention Deficit Disorder with Hyperactivity | Dec 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Lisdexamfetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor | SLC6A3, SLC6A2, SLC18A2 | Phase 2 | Methamphetamine Abuse | Dec 2027 |
| University of Rochester | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Chronic Pain | Dec 2027 |
| Russell McCulloh, MD | Phentermine Norepinephrine transporter releasing agent | SLC6A2 | Phase 2 | Childhood Obesity | Jan 2028 |
| Icahn School of Medicine at Mount Sinai | Atomoxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 2 | Melanocortin Obesity Syndrome | Mar 2028 |
| Prof. Dr. Frank Behrens | DEX IR tablets Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin | SLC6A3, SLC6A2 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Mar 2028 |
| Prof. Dr. Frank Behrens | DEX XL Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin | SLC6A3, SLC6A2 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Mar 2028 |
| University of Rochester | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Painful Peripheral Neuropathy | Jun 2028 |
| Wright State University | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Rosacea | Dec 2028 |
| University of Michigan | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Quiescent Crohn's Disease (CD) | Dec 2029 |
| Md. Moktadirul Hoque Shuvo | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Functional Dyspepsia | – |
| First Affiliated Hospital of Chongqing Medical University | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 1 | Depression | Dec 2026 |
| Brigham and Women's Hospital | [C-11]Methylreboxetine ([C-11]MRB) Norepinephrine transporter (NET) radioligand for PET imaging | SLC6A2 | Phase 1 | Multiple Sclerosis | Dec 2026 |
| Resilient Pharmaceuticals | Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 1 | Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder … | Feb 2027 |
| St. Jude Children's Research Hospital | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 1 | Sickle Cell Disease | Jul 2027 |
| Brigham and Women's Hospital | Atomoxetine-plus-oxybutynin (AtoOxy) Norepinephrine reuptake inhibitor combined with muscarinic antagonist to activate pharynge | SLC6A2, CHRM1 | Phase 1 | Obstructive Sleep Apnea | Sep 2028 |
| Rachel Yehuda | MDMA Hydrochloride Serotonin-norepinephrine-dopamine releasing agent; promotes prosocial behavior and emotion | SLC6A4, SLC6A2, SLC6A3 | Phase 1 | Mental Wellbeing | Sep 2029 |
| Satish R. Raj | Atomoxetine Norepinephrine transporter inhibitor | SLC6A2 | Phase 1 | Tachycardia | Dec 2029 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | [18F]-6F-DA Fluorine-18 labeled dopamine analog entering cells via norepinephrine transporter (NET) an | SLC6A2, SLC18A1 | Phase 1 | Pheochromocytoma | Nov 2048 |
| Massachusetts General Hospital | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 1 | Brain Injury Traumatic Severe (Diagnosis) | – |
Obstructive Sleep Apnea (6) Post Traumatic Stress Disorder (6) Posttraumatic Stress Disorder (5) ADHD (5) Prostate Cancer (3) Obesity (3) Multiple Sclerosis (3) Attention Deficit Hyperactivity Disorder (ADHD) (3) PTSD (3) Major Depressive Disorder (3) Attention-Deficit/Hyperactivity Disorder (ADHD) (3) Schizophrenia (3)
small molecule (80), protein or peptide (5), mixed (3)
Brigham and Women's Hospital (3) Axsome Therapeutics (3) University of Pennsylvania (2) Wright State University (2) University of Rochester (2) VA Office of Research and Development (2) M.D. Anderson Cancer Center (2) University of Haifa (2) Medical University of Lodz (2) Sunnybrook Health Sciences Centre (2) University of California, Irvine (2) All India Institute of Medical Sciences, Bhubaneswar (2) Daniel Coury (2) Vrije Universiteit Brussel (2) Prof. Dr. Frank Behrens (2) Aarhus University Hospital (1) Johns Hopkins University (1) Parc de Salut Mar (1) First Affiliated Hospital of Chongqing Medical University (1) Rachel Yehuda (1)
SLC6A3 (38) SLC6A4 (34) OPRM1 (2) SLC18A2 (2) GRIN1 (1) SLC18A1 (1) SLC5A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) NR3C2 (1) AGTR1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.